U.S. Healthcare Services Stock News

NasdaqGS:AVPT
NasdaqGS:AVPTSoftware

How Investors May Respond To AvePoint (AVPT) Launching AgentPulse For Multicloud AI Agent Governance

In early March 2026, AvePoint announced the past general availability of its AgentPulse Command Center, expanding multicloud observability and governance for autonomous AI agents across Microsoft 365 and Google Cloud, with unified monitoring, lifecycle management, and cost controls to reduce shadow AI, data exposure, and surprise usage bills. A distinctive feature is the single-pane view across Copilot Studio, Microsoft Foundry, SharePoint agents, and Vertex AI, giving enterprises...
NYSE:LYV
NYSE:LYVEntertainment

Why Live Nation (LYV) Is Down 5.3% After DOJ Antitrust Settlement And Extended Oversight

Live Nation Entertainment has settled the US Department of Justice’s antitrust lawsuit without admitting wrongdoing, extending its consent decree by eight years and setting up a US$280 million fund to address state damages claims. The agreement lets Live Nation retain Ticketmaster under stricter operating conditions while leaked internal messages and ongoing state actions keep its ticketing practices under intense scrutiny. We’ll now examine how the extended DOJ consent decree and continuing...
NasdaqGS:FTDR
NasdaqGS:FTDRConsumer Services

Frontdoor (FTDR) Valuation Check After Strong Q4 Beat And Softer Full Year Guidance

Frontdoor (FTDR) is back in focus after reporting Q4 revenue of $433 million, a 13.1% year over year increase, along with earnings that exceeded expectations and full year revenue guidance slightly below projections. See our latest analysis for Frontdoor. Since the earnings release, Frontdoor’s share price has moved to US$64.22, with a 13.38% 1 month share price return and a 69.58% 1 year total shareholder return, which may suggest building momentum despite some recent short term pullback. If...
NYSE:LEU
NYSE:LEUOil and Gas

Centrus Energy (LEU) Is Up 8.7% After Oklo JV, AI Push Reframe Nuclear Fuel Role – What’s Changed

In March 2026, Oklo Inc. and Centrus Energy agreed to pursue a joint venture for high-assay low-enriched uranium deconversion at Centrus’ Piketon, Ohio site, while Centrus also reported lower-than-expected quarterly earnings affected by a delayed Russian shipment and outlined increased capital spending plans. Centrus’ recent collaboration with Palantir on AI-driven enrichment optimization and its talks with Oklo on an integrated HALEU hub highlight how technology and fuel-cycle partnerships...
NasdaqGS:UBSI
NasdaqGS:UBSIBanks

Is United Bankshares (UBSI) Still Sensibly Priced After The Recent Share Price Pullback?

Wondering if United Bankshares at around US$39.38 is still a fair deal or starting to look stretched? This article breaks down what the current share price might be implying about value. The stock’s returns range from a 1.4% decline over the last 7 days and a 10.7% decline over the last 30 days, to gains of 2.6% year to date, 17.5% over 1 year, 25.7% over 3 years and 25.2% over 5 years. These figures can mean very different things depending on how you think about risk and timing. Recent...
NasdaqGS:ORLY
NasdaqGS:ORLYSpecialty Retail

O'Reilly Automotive Debt Issuance Raises Questions On Long Term Flexibility

O'Reilly Automotive completed a significant fixed income offering of senior unsecured notes due in 2036. The transaction adds long dated debt to the company’s balance sheet, which may affect its capital structure and liquidity profile. The terms of the notes and investor demand can offer clues about how credit markets currently view O'Reilly Automotive, ticker NasdaqGS:ORLY. Investors watching NasdaqGS:ORLY now have a fresh data point to consider alongside the current share price of $90.46...
NasdaqGS:XRAY
NasdaqGS:XRAYMedical Equipment

Is Dentsply Sirona's (XRAY) Dental‑Dedicated MRI Bet Quietly Redefining Its Competitive Moat?

Dentsply Sirona and Siemens Healthineers recently received US FDA clearance for the MAGNETOM Free.Max Dental Edition, the first dental‑dedicated MRI system clinically validated for multiple specialties including endodontics, periodontics, TMJ, orthodontics, and tooth extraction. This non‑ionizing, dental‑specific MRI platform, with a focused field of view and sub‑20‑minute workflow, could meaningfully enhance complex diagnostic capabilities in hospitals, large clinics, and academic...
NasdaqGM:TLS
NasdaqGM:TLSSoftware

Telos (TLS) Q4 Loss Rebound Challenges Bullish Margin Improvement Narratives

Telos (TLS) just closed out FY 2025 with Q4 revenue of US$46.8 million and a basic EPS loss of US$0.22, capping a year in which trailing twelve month revenue came in at US$164.8 million and EPS on the same basis was a loss of US$0.50. Over recent quarters the company has seen revenue move from US$26.4 million in Q4 2024 to US$30.6 million in Q1 2025, US$36.0 million in Q2, US$51.4 million in Q3, and US$46.8 million in Q4, while quarterly basic EPS losses ranged between US$0.03 and US$0.22...
NYSE:FLO
NYSE:FLOFood

Assessing Flowers Foods (NYSE:FLO) Valuation After Q4 Impairment And Turnaround Hopes

Event driven setup around Flowers Foods Recent commentary around Flowers Foods (FLO) focuses on its large Q4 non cash impairment charge, which has stirred investor skepticism even as some market watchers argue the stock reaction looks harsher than the underlying fundamentals. See our latest analysis for Flowers Foods. At a share price of $8.89, Flowers Foods has seen a 14.2% decline over the past month and a 19.3% decline over the past quarter on a share price return basis. The 1 year total...
NasdaqGS:WAY
NasdaqGS:WAYHealthcare Services

A Look At Waystar Holding (WAY) Valuation As Google Cloud AI Partnership Gains Traction

AI partnership expansion with Google Cloud comes into focus Waystar Holding (WAY) is back on investor radars after announcing an expanded collaboration with Google Cloud that centers on deeper use of Gemini AI models and data infrastructure in healthcare payments. The move targets more automation across complex revenue cycle workflows, including new agentic AI use cases that combine financial and clinical data, and could influence how investors think about the company’s long term technology...
NasdaqGS:ITRN
NasdaqGS:ITRNCommunications

Stronger Earnings And Bigger Capital Returns Could Be A Game Changer For Ituran (ITRN)

Ituran Location and Control Ltd. recently reported higher fourth‑quarter and full‑year 2025 earnings, approved a US$1.50 per‑share cash dividend totaling about US$30.00 million to be paid on April 16, 2026, and completed a US$25.42 million share buyback while authorizing an additional US$10.00 million for repurchases. The combination of earnings growth, a sizable dividend drawn from “Preferred Income” and “Preferred Technological Income” at a reduced 20% withholding tax rate, and an expanded...
NasdaqGS:DYN
NasdaqGS:DYNBiotechs

Is Dyne’s Phase 3 HARMONIA Launch Reframing The Investment Case For Dyne Therapeutics (DYN)?

Dyne Therapeutics recently advanced its neuromuscular pipeline, initiating the global Phase 3 HARMONIA trial of z-basivarsen for myotonic dystrophy type 1 and releasing new 24‑month data from the Phase 1/2 DELIVER trial of z-rostudirsen in Duchenne muscular dystrophy, alongside reporting a full-year 2025 net loss of US$446.21 million. With FDA alignment on HARMONIA’s confirmatory design, multiple regulatory designations for both assets, and additional long-term cardiopulmonary data in DMD,...
NasdaqGS:LFCR
NasdaqGS:LFCRLife Sciences

Lifecore Biomedical (LFCR) Q4 Loss Narrows To US$2 Million Reinforcing Bullish Margin Narratives

Lifecore Biomedical (LFCR) just posted its FY 2025 fourth quarter numbers, with revenue of US$36.4 million and a basic EPS loss of US$0.06. This sets the tone for a year where the trailing twelve months show revenue at about US$129.5 million and a basic EPS loss of US$0.92. Over recent quarters, revenue has moved from US$24.7 million in Q1 FY 2025 to US$31.1 million in Q3 and then US$36.4 million in Q4. Quarterly basic EPS losses ranged from US$0.53 in Q1 to US$0.29 in Q3 and US$0.06 in Q4,...
NasdaqGS:TRS
NasdaqGS:TRSPackaging

Assessing TriMas (TRS) Valuation After Recent Share Price Momentum And Undervaluation Narrative

Why TriMas is on investors’ radar today TriMas (TRS) has drawn fresh interest as investors look at its recent share performance alongside its value score of 3 and current market capitalization of about US$1.32b. The stock shows a 1 day return of 1.23%, a month return decline of 2.21%, and a past 3 months return of 3.77%, while the 1 year total return stands at 42.54%. See our latest analysis for TriMas. The recent 1 day share price gain of 1.23% to US$35.47 comes after a weaker 7 day and year...
NYSE:LTC
NYSE:LTCHealth Care REITs

Is LTC Properties (LTC) Offering Value After Strong Multi Year Share Price Gains

If you are wondering whether LTC Properties at around US$38.99 is offering good value today, it helps to step back and look at what the recent share performance and fundamentals are really telling you. The stock has delivered a 0.6% return over the last week, a 1.0% decline over the past month, and is up 12.5% year to date and 15.5% over the past year, with longer term returns of 41.0% over three years and 26.1% over five years. Recent attention on LTC Properties has focused on its position...
NYSE:ED
NYSE:EDIntegrated Utilities

Does New US$3.5 Billion Credit Line And EPS Targets Change The Bull Case For Consolidated Edison (ED)?

Consolidated Edison recently entered into a new US$3.50 billions revolving credit facility to support its commercial paper programs and general corporate purposes, shortly after reporting Q4 2025 revenue and adjusted EPS that topped Wall Street expectations. Together with management’s plans for a five-year adjusted EPS compound annual growth rate of 6% to 7%, the expanded credit access highlights how the utility is prioritizing both liquidity and earnings visibility. We’ll now look at how...
NYSE:BEKE
NYSE:BEKEReal Estate

KE Holdings (NYSE:BEKE) Margin Compression Tests Premium P/E And Bullish Growth Narrative

KE Holdings (NYSE:BEKE) FY 2025 Results Overview KE Holdings (NYSE:BEKE) has wrapped up FY 2025 with fourth quarter revenue of C¥22.2b and basic EPS of C¥0.08, alongside trailing 12 month revenue of C¥94.6b and basic EPS of C¥2.70 that frame the latest print for investors watching the stock around C¥16.90 per share. The company has seen quarterly revenue range from C¥22.1b to C¥26.0b over the past year, with basic EPS moving between C¥0.08 and C¥1.16 across FY 2025. This gives a clearer view...
NYSE:ABBV
NYSE:ABBVBiotechs

What AbbVie (ABBV)'s Early ABBV-295 Obesity Data Means For Shareholders

Earlier this month, AbbVie reported positive Phase 1 multiple-ascending-dose results for its investigational obesity drug ABBV-295, a long-acting amylin analog that induced clinically meaningful, dose-dependent weight loss with generally mild gastrointestinal side effects over 12–13 weeks of treatment. The data highlight AbbVie’s push into a mechanistically distinct class of obesity therapies beyond incretin-based drugs, adding another potential pillar to its already broad pipeline in...
NYSE:ZEPP
NYSE:ZEPPElectronic

Zepp Health (ZEPP) Q4 Loss Narrows To US$0.69 EPS Challenging Bearish Profitability Narratives

Zepp Health (ZEPP) has wrapped up FY 2025 with fourth quarter revenue of US$85.2 million and a basic EPS loss of US$0.69, setting the tone for how you might read the full year at the current share price of US$16.22. The company has seen quarterly revenue move from US$59.5 million in Q4 2024 to US$85.2 million in Q4 2025, while basic EPS over that stretch has shifted from a loss of US$2.29 to a loss of US$0.69. This puts the focus squarely on how sustainably margins can tighten those losses...
OTCPK:DIDI.Y
OTCPK:DIDI.YTransportation

A Look At DiDi Global (OTCPK:DIDI.Y) Valuation After Revenue Growth And Softer Profitability

Why DiDi Global’s latest earnings matter for shareholders DiDi Global (OTCPK:DIDI.Y) has released fourth quarter and full year 2025 results, with higher reported sales alongside a quarterly net loss and lower annual net income, giving you a mixed profitability picture to weigh. For the fourth quarter, DiDi Global reported sales of CNY 58,445 million compared with CNY 52,914 million a year earlier, and a net loss of CNY 338 million versus a CNY 1,341 million loss in the prior year...
NasdaqGS:ROST
NasdaqGS:ROSTSpecialty Retail

Ross Stores Expansion Tests Off Price Model And Community Focus In 2026

Ross Stores (NasdaqGS:ROST) is opening 17 new locations across 11 U.S. states as part of its 2026 expansion plan. The openings mark the first phase of a targeted 110 new stores the company aims to add this fiscal year. Each grand opening includes charitable contributions to local youth organizations in the surrounding communities. Ross Stores operates off price retail banners that focus on discounted apparel and home goods, a segment that often attracts value oriented shoppers. The decision...
NasdaqGS:ACAD
NasdaqGS:ACADBiotechs

ACADIA Pharmaceuticals (ACAD) Is Down 5.3% After EMA Rejects Trofinetide In Rett Review - What's Changed

Earlier in February 2026, ACADIA Pharmaceuticals received a formal negative opinion from the EMA’s CHMP on its marketing application for trofinetide in Rett syndrome, while also appointing biopharma finance executive Jonathan M. Poole to its Board and preparing a leadership presentation at the Longwood Healthcare Leaders Miami conference. This mix of regulatory setback in Europe and added financial expertise on the Board highlights a pivotal moment for ACADIA’s rare disease and CNS growth...
NasdaqGS:VNET
NasdaqGS:VNETIT

VNET Group (NasdaqGS:VNET) EPS Loss Deepens In Q3 2025 Challenging Profitability Narratives

VNET Group (NasdaqGS:VNET) just reported FY 2025 third quarter revenue of C¥2.6b with a basic EPS loss of C¥1.14, while trailing twelve month revenue stood at C¥9.5b alongside a basic EPS loss of C¥2.17. The company has seen quarterly revenue move from C¥2.0b in Q2 2024 to C¥2.1b in Q3 2024, C¥2.2b in Q4 2024 and Q1 2025, C¥2.4b in Q2 2025 and now C¥2.6b in Q3 2025, with EPS swinging between a profit of C¥1.19 in Q3 2024 and losses including C¥0.89 in Q1 2025 and C¥1.14 in the latest quarter...
NasdaqGS:SAIC
NasdaqGS:SAICProfessional Services

SAIC (SAIC) Earnings Growth And 5% Margin Reinforce Bullish Profitability Narratives

Science Applications International (SAIC) has just posted fresh FY 2026 numbers, with third quarter revenue of US$1,866 million and basic EPS of US$1.70, alongside trailing 12 month revenue of US$7.4 billion and EPS of US$7.86. Over recent quarters the company has seen revenue range from US$1,769 million to US$1,877 million and quarterly EPS move between US$1.43 and US$2.72. This gives investors a clearer view of how the current run rate feeds into those trailing figures. With trailing net...